Chronic, recurrent Lymphocytic Leukemia Recruiting Phase 1 / 2 Trials for Cyclophosphamide (DB00531)

Also known as: Recurrent Chronic Lymphocytic Leukemia

IndicationStatusPhase
DBCOND0112002 (Chronic, recurrent Lymphocytic Leukemia)Recruiting1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03277729A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin LymphomasTreatment